Table 2 Disease response rates at 3 and 6 months in the total population (N=44)

From: Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

 

Total Population ( N =44)

Endometrioid histology ( n =28)

Serous histology ( n =11)

Other histology ( n =5)

Response, n (%)

3 Months

6 Months

3 Months

6 Months

3 Months

6 Months

3 Months

6 Months

Non-progressive disease

16 (36)

16 (36)

11 (39)

11 (39)

3 (27)

3 (27)

2 (40)

2 (40)

Complete response

Partial response

2 (5)

4 (9)

1 (4)

3 (11)

1 (9)

1 (9)

0

0

Stable disease

14 (32)

12 (27)

10 (36)

8 (29)

2 (18)

2 (18)

2 (40)

2 (40)

Progressive disease

25 (57)

25 (57)

15 (54)

15 (54)

8 (73)

8 (73)

2 (40)

2 (40)

Not evaluable

3 (6)

3 (6)

2 (7)

2 (7)

0

0

1 (20)

1 (20)